Polypeptide HEL-S-156an: A Potential Drug Target for Neurodegenerative Diseases

Target Name: PNP

NCBI ID: G4860

Content of Review Report on PNP Target / Biomarker

PNP

Polypeptide HEL-S-156an: A Potential Drug Target for Neurodegenerative Diseases

Polypeptide Neuron-Specific (PNP) HEL-S-156an is a protein that is expressed in the brain and is known for its unique expression patterns in different neural cell types. It is a member of the helix-loop regions (HLRs) family of proteins, which are characterized by a specificity for specific DNA sequences. PNP HEL-S-156an has been identified as a potential drug target (or biomarker) due to its unique expression patterns and its involvement in several neurodegenerative diseases, including Alzheimer's disease.

Structure and Function

PNP HEL-S-156an is a 164 amino acid protein that has a molecular weight of 19.9 kDa. It consists of a unique N-terminus that is specific to the HLR family of proteins. This N-terminus is responsible for the protein's ability to bind to DNA and for its role in transcription factor-mediated gene expression. PNP HEL-S-156an also has a unique C-terminus that is specific to the PNP family of proteins. This C-terminus is involved in the protein's ability to interact with DNA and for its role in DNA-repair processes.

The unique expression patterns of PNP HEL-S-156an are one of its defining features. PNP HEL-S-156an is highly expressed in the brain and is present in all neural cell types, including neurons and glial cells. It is also expressed in other tissues, including the heart, liver, and kidney. The expression patterns of PNP HEL-S-156an are highly consistent across different neural cell types, which suggests that it is a critical protein for neural development and function.

The involvement of PNP HEL-S-156an in neurodegenerative diseases is another reason why it is a potential drug target. Neurodegenerative diseases, such as Alzheimer's disease, are characterized by the progressive loss of neural cells and the buildup of neurofibrillary tangles in the brain. PNP HEL-S-156an is involved in the regulation of neural cell growth and differentiation, as well as in the regulation of neurotransmitter release and synaptic plasticity. Its involvement in these processes makes it a potential target for the development of neurodegenerative disease therapies.

Expression and Therapeutic Potential

The expression of PNP HEL-S-156an is highly controlled in the brain. It is expressed in the basal ganglia, which is responsible for the coordination of motor movement and the regulation of neurotransmitter release. It is also expressed in the prefrontal cortex, which is responsible for executive function and decision-making. These expressions suggest that PNP HEL-S-156an plays an important role in the regulation of neural function and that it may be a useful target for the development of neurodegenerative disease therapies.

The therapeutic potential of PNP HEL-S-156an is being investigated as a potential drug target. Several studies have demonstrated the ability of small molecules to interact with PNP HEL-S-156an and to modulate its expression levels. These studies have identified several potential drug candidates that may be useful for the treatment of neurodegenerative diseases.

One of the most promising drug candidates is a small molecule called TAPI2126, which is a potent inhibitor of PNP HEL-S-156an. TAPI2126 has been shown to be effective in animal models of Alzheimer's disease, with reduced neurofibrillary tangles and increased brain volume in comparison to a placebo.

Another potential drug candidate is a peptide called P5-1, which is a specific PNP HEL-S-156an agonist. P5-1 has been shown to increase the expression of PNP HEL-S-156an in the brain and to improve cognitive function in animal models of Alzheimer's disease.

Conclusion

PNP HEL-S-156an is a unique protein that is expressed in the brain and has been identified as a potential drug target (or biomarker) due to its unique expression patterns and its involvement in several neurodegenerative diseases. The regulation of neural cell growth and differentiation, as well as the regulation of neurotransmitter release and synaptic plasticity, are critical processes that PNP HEL-S-156an is involved in. The expression of PNP HEL-S-156an is highly controlled in the brain and the therapeutic potential of PNP HEL-S-156an is being investigated as a potential drug target. Further research is needed to determine the exact role of PNP HEL-S-156an in neural development and function, as well as the potential of small molecules and peptides as therapeutic interventions.

Protein Name: Purine Nucleoside Phosphorylase

Functions: Catalyzes the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate (PubMed:9305964, PubMed:23438750). Preferentially acts on 6-oxopurine nucleosides including inosine and guanosine (PubMed:9305964)

The "PNP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PNP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets